TSTickerStarGet alerts

Cellectis Reports Q3 2026 Results; Announces Strategic Pivot to In Vivo Gene Editing

Cellectis S.A. reported a net loss of $101.1 million for the nine-month period ended September 30, 2026, compared to a net loss of $41.3 million in the prior-year period, as revenues declined 76% to $14.8 million driven by lower activity under the AstraZeneca collaboration. The company announced a strategic transformation to become an in vivo gene editing company focused on chronic diseases, exiting development of lasme-cel and eti-cel while advancing.HEAL-101 and.HEAL-201 programs. The company recognized $26.8...

Share this story

Key takeaways

  • Strategic pivot: Company announced transition to in vivo gene editing company focused on developing treatments for chronic diseases, exiting lasme-cel and eti-cel programs while seeking strategic partnering opportunities.

  • New pipeline programs: .HEAL-101 targets APOC3 for severe hypertriglyceridemia with Phase 1 IIT in China planned (data expected H2 2027); .HEAL-201 targets PCSK9 for severe hypercholesterolemia with Phase 1 IIT planned (data expected H1 2028).

  • Restructuring charges: $34.9 million impact from strategic transformation including $26.6 million impairment on Raleigh and Paris facilities, $6.2 million in termination benefits, and $2.1 million in program close-out costs.

  • Financial guarantee exposure: $9.4 million ECL allowance recognized on lease guaranty for Cibus (formerly Calyxt) Roseville, Minnesota facility following landlord complaint; total potential undiscounted exposure of $18.8 million.

  • Cash position: $28.2 million in cash and cash equivalents plus $118.3 million in fixed-term deposits as of September 30, 2026; company expects sufficient funds into H2 2028 after restructuring.

  • AstraZeneca collaboration: $14.0 million revenue recognized from AZ JRCA in Q3 2026; milestone structure amended to up to $253 million per product candidate (up from $220 million).

Key metrics

Total revenuesNine months ended September 30, 2026
$14.8 million-76.4%
Collaboration agreement revenuesNine months ended September 30, 2026
$14.1 million-77.3%
Net lossNine months ended September 30, 2026
$101.1 million144.8% increase in loss
Basic/diluted net loss per shareNine months ended September 30, 2026
($1.00)From ($0.41)
Total revenuesThree months ended September 30, 2026
$3.8 million-89.3%
Net lossThree months ended September 30, 2026
$61.5 millionFrom net income of $0.6 million
Basic/diluted net loss per shareThree months ended September 30, 2026
($0.61)From $0.01
Net cash used in operating activitiesNine months ended September 30, 2026
($45.9 million)From ($29.0 million)

Customer concentration

AstraZenecaNine months ended September 30, 2026
95%Share of revenue

Disclosure changes

  • Strategic transformation

    Company announced strategic pivot to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases, exiting development of lasme-cel and eti-cel while seeking strategic partnering opportunities. The realignment will reduce global headcount by up to 70% from pre-transition levels over 2026-2027.

    Fundamental shift in business strategy and pipeline priorities; significant restructuring charges; extended cash runway
  • Impairment testing and asset impairments

    Company recognized $26.8 million impairment loss on right-of-use assets ($2.1 million) and property, plant and equipment ($24.8 million) related to Raleigh and Paris facilities following strategic transformation and changes in expected use of assets.

    Significant non-cash charge reflecting reduced asset values due to strategic pivot and exit from cell therapy manufacturing
  • Financial guarantee and expected credit loss

    Company recognized $9.4 million expected credit loss allowance on financial guarantee for Cibus (formerly Calyxt) Roseville, Minnesota lease following September 2026 landlord complaint seeking recovery of alleged defaults under lease and guaranty; total potential undiscounted exposure of $18.8 million.

    Material contingent liability related to former Calyxt subsidiary; ongoing litigation with landlord
  • Restructuring provisions

    Company recognized $6.1 million in termination benefits provisions for restructuring plan in U.S. and France, $1.0 million for lasme-cel and eti-cel program close-out activities, and $0.9 million for leased premises restoration costs.

    Significant restructuring charges associated with strategic transformation and workforce reduction
  • AstraZeneca collaboration milestone structure

    On November 17, 2025, AZ Ireland and Cellectis amended the JRCA to prospectively change milestone payment structure to up to $253 million per product candidate (up from up to $220 million previously) for each of up to 10 candidate products.

    Increased potential milestone value from AstraZeneca collaboration; reflects enhanced partnership terms
  • EIB warrant fair value changes

    Fair value gain of $15.1 million on Tranche A, B, and C warrants issued to European Investment Bank recognized in nine months ended September 30, 2026, compared to $5.8 million fair value loss in prior year period.

    Significant non-cash fair value adjustment on derivative instruments; reflects changes in company share price and volatility assumptions

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow CLLS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert